🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03752892
Active, not recruiting Not applicable

Partitioned Training of Patients With Idiopathic Pulmonary Fibrosis

NCT03752892 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2019-03-01
Last updated
2026-08-20

Condition(s) studied

Lung; Disease, Interstitial, With Fibrosis

Investigational drug(s) / intervention(s)

intervention -1-leg cycle trainingusual care - 2-leg cycle training

intervention -1-leg cycle training: partitioned aerobic exercise training

usual care - 2-leg cycle training: conventional aerobic exercise training

Study summary

Idiopathic pulmonary fibrosis (IPF) is a lung disease that limits the ability to breathe enough for a good workout. One way to improve the exercise training is to reduce the number of muscles being trained together. By training one leg at a time, the patient does not have to breathe as much allowing each leg a better workout. Our groundwork suggests it may work in patients with IPF. This study will help decide whether one-legged exercise training is better at improving a patient's exercise endurance compared to the usual way of exercising with both legs at the same time.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * confirmed idiopathic pulmonary fibrosis * Clinically stable * enrolled in pulmonary rehabilitation Exclusion Criteria: * co-morbidities that might impair their ability to safely complete a pulmonary rehabilitation program * complete a pulmonary rehabilitation program within the previous 6 months * experienced an exacerbation less than six weeks before participation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
West Park Healthcare Centre Toronto Ontario

More West Park Healthcare Centre trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03752892 on ClinicalTrials.gov ↗ ← All trials in Canada